International Stem Cell (ISCO) Return on Capital Employed (2011 - 2026)
International Stem Cell (ISCO) posted quarterly Return on Capital Employed of 56.63% for Q4 2025, down 4271.0% year-over-year from 1.36% in Q4 2024, and down 543.39% quarter-over-quarter from 12.77% in Q3 2025.
International Stem Cell (ISCO) Return on Capital Employed (2011 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Return on Capital Employed for 15 consecutive years, with 56.63% the latest figure, recorded in Q4 2025.
- In Q4 2025, Return on Capital Employed fell 4271.0% year-over-year to 56.63%; the TTM figure through Dec 2025 stood at 56.63% (down 4271.0% YoY), while the FY2025 annual figure was 64.03%, down 5257.0% from the prior year.
- Return on Capital Employed fell to 56.63% in Q4 2025 per ISCO's latest filing, from 12.77% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.77% in Q3 2025 and bottomed at 321.7% in Q1 2022.
- Historically, Return on Capital Employed has averaged 116.67% across 5 years, with a median of 86.61% in 2022.
- Annual changes were most pronounced in 2021 — Return on Capital Employed tumbled 22290 bps — and 2023, when it soared 27108 bps.
- International Stem Cell's Return on Capital Employed stood at 291.86% in 2021, then soared by 86 bps to 40.35% in 2022, then sank by 140 bps to 97.0% in 2023, then soared by 86 bps to 13.92% in 2024, then slumped by 307 bps to 56.63% in 2025.
- Business Quant data shows ISCO's Return on Capital Employed at 56.63% in Q4 2025, 12.77% in Q3 2025, and 13.46% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 187.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.10% |
| Dec 31, 2025 | -56.63% |
| Sep 30, 2025 | 12.77% |
| Jun 30, 2025 | -13.46% |
| Mar 31, 2025 | -36.14% |
| Dec 31, 2024 | -13.92% |
| Sep 30, 2024 | -81.17% |
| Jun 30, 2024 | -120.22% |
| Mar 31, 2024 | -203.87% |
| Dec 31, 2023 | -97.00% |
| Sep 30, 2023 | -17.26% |
| Jun 30, 2023 | -46.49% |
| Mar 31, 2023 | -50.61% |
| Dec 31, 2022 | -40.35% |
| Sep 30, 2022 | -92.05% |
| Jun 30, 2022 | -116.42% |
| Mar 31, 2022 | -321.70% |
| Dec 31, 2021 | -291.86% |
| Sep 30, 2021 | -251.78% |
| Jun 30, 2021 | -180.92% |